Now, the same patches are being recast as a potential life-prolonging treatment for men. For years, debates around HRT have focused on its risks and benefits for women navigating menopause, with strong views on both sides. It is also a striking example of how women’s health and men’s health intersect. That conversation may feel more like choosing between HRT options in the menopause clinic than the old, paternalistic model of cancer care where one default protocol is imposed. What the study does immediately is widen the menu of choices. Cost-effectiveness analyses and real-world data will follow.. Testicular changes with aging include loss of Leydig cells, decreased testosterone production, and decreased responsiveness of the testes to luteinizing hormone (LH) Rubens et al. 1974; Neaves et al. 1984. Accordingly, in the Baltimore Longitudinal Study on Aging (BLSA), roughly 10% of men in their 40s and 25% of men in their 70s were hypogonadal, based on serum testosterone levels Harman et al. 2001. The two principal androgens in men are testosterone, produced by testicular Leydig cells, and dihydrotestosterone (DHT), produced from testosterone in peripheral tissues by 5-α reductase.|In multiple high-quality studies, testosterone therapy in men with low testosterone levels does not increase the risk of prostate cancer compared to men who didn’t receive the treatment. A study published online Dec. 27, 2023, by JAMA Network Open confirms prior research showing that testosterone replacement therapy (TRT) in men with documented low testosterone levels does not increase their risk of prostate cancer compared to men not using TRT. Lowering testosterone levels, known as androgen deprivation therapy, became the standard treatment for advanced prostate cancer. Even more surprisingly, doctors are testing a new approach in certain men with prostate cancer called bipolar androgen therapy, which switches testosterone levels between very low and very high. Using a combination of genetic, biochemical, and chemical approaches, the research team defined the mechanisms that enable prostate cancer cells to recognize and respond differently to varying levels of testosterone, the most common androgenic hormone. Hormone therapy is a prostate cancer treatment that removes hormones that cancer cells need to grow.|We attempt to make important distinctions between patient populations and sources of testosterone.|Adenocarcinomas start in the cells of glands that secrete fluid, like your prostate. Prostate cancer starts in the prostate gland, part of the male reproductive system. Here is how to take a cautious approach to testosterone therapy.}
They identified an inverse association of PrCa with SHBG, but not serum testosterone, with a relative risk (RR) of 0.86 Roddam et al. 2008. The placebo arm included 3242 patients between the ages of 50 and 75 years who all had at least one prior negative prostate biopsy. A large study of untreated hypogonadal men with prostate-specific antigen (PSA) Morgentaler and Rhoden, 2006. Lastly, Shaneyfelt and colleagues performed a meta-analysis of three prospective nested case-control studies, including the study by Gann and colleagues. Several longitudinal studies have established a relationship between elevated testosterone and subsequent development of PrCa. Current laboratory data demonstrate that many well-differentiated PrCa cell lines are androgen responsive and undergo programmed cell death upon androgen withdrawal Kyprianou et al. 1990; Webber et al. 1996; Schwab et al. 2000. In 1941, Huggins and Hodges proposed that PrCa growth was driven by androgens, after observing the benefits of castration in PrCa patients Huggins and Hodges, 1941.|Hormone therapy can help make other treatments more effective but doesn’t cure prostate cancer by itself. Hormone therapy is usually among the first treatments doctors use for advanced prostate cancer. Hormone therapy is a common treatment for advanced prostate cancer or cancer that has returned after treatment. The old belief that testosterone therapy increases prostate cancer or makes it worse is no longer backed up by modern research. None of this means testosterone replacement therapy – for men with low testosterone levels – is completely without risk. Testosterone has shifted from a presumed villain feared to ignite prostate cancer, to a hormone whose effects are more complex than once believed, and even a possible ally in the fight against prostate cancer. This is why many men eventually develop castration-resistant prostate cancer, where the disease progresses and can become more aggressive despite near-zero testosterone.}
"Nature has designed a system where low doses of hormones stimulate cancer cell proliferation and high doses cause differentiation and suppress growth, enabling the same hormone to perform diverse functions," McDonnell said. In doing so, it activates the pathways that cause cancer cells to grow and spread. When androgen levels are low, the androgen receptor is encouraged to "go solo" in the cell. Hormone therapy also increases the likelihood of other treatment options, such as radiation therapy, being effective. Androgens can also help prostate cells grow by connecting to proteins that express the genes that lead to growth.
Tony and Ramiro recently came together to provide play-by-play commentary, not on football, but of advanced prostate cancer patients and their caregivers, fostering a deeper appreciation for everyday moments, both big and small. The Romos encourage men with advanced prostate cancer and their caregivers to have a game plan in place when discussing treatment options, like NUBEQA® (darolutamide), with their doctor. With the campaign, Highlights REAL, they are spotlighting the everyday experiences of advanced prostate cancer patients and their families. Regulators will need to approve oestradiol patches specifically for prostate cancer, not just menopause, before health systems such as the NHS can routinely offer them in this way. Most prostate cancers diagnosed in the early stages can be cured with treatment. As with cancer in general, prostate cancer forms when cells divide faster than usual. Early-stage prostate cancer rarely causes symptoms.
For some men, symptoms of prostate cancer can include frequent urination, painful ejaculation, erectile dysfunction, or blood in the urine. "I hope this campaign inspires others to appreciate the small, meaningful moments in life and take proactive steps when it comes to prostate cancer screening and treatment management. "Partnering with Bayer has allowed me to engage in some of the most meaningful work of my career—spotlighting the everyday experiences of patients with advanced prostate cancer," Tony says.
There is large body of both historic and modern data supporting a role for androgens in PrCa pathogenesis and progression, also known as the ‘androgen hypothesis’. Importantly, the inclusion of symptoms in the diagnosis of LOH helps to separate the pathologic condition of LOH from normal, and expected, age-dependent declines in testosterone (Figure 1). Older men also demonstrate decreased amplitude and slowing of LH pulses and this hypothalamic dysfunction in LOH is characterized by low-normal LH levels, even in the presence of low testosterone Bremner et al. 1983; Tenover et al. 1988. In a subset of men, the age-related decline in androgens will lead to signs and symptoms of hypogonadism, termed LOH or androgen deficiency in the aging male (ADAM). Serum androgen levels in men steadily decline with age, beginning in the fourth decade of life Harman et al. 2001; Mulligan et al. 2006; Basaria, 2014.